You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)在第66屆ASH年會上公佈CS5001針對晚期淋巴瘤的最新臨牀數據
格隆匯 12-09 08:04

格隆匯12月9日丨基石藥業-B(02616.HK)發佈公吿,公司將在第66屆美國血液學會(ASH)年會上公佈管線2.0重磅產品CS5001(ROR1 ADC)針對淋巴瘤的最新臨牀數據。

根據披露,CS5001是目前已知首個在實體瘤和淋巴瘤中均觀察到臨牀療效的ROR1 ADC。本次ASH年會的公佈突出了CS5001作為單藥治療晚期淋巴瘤的最新安全性和療效數據。CS5001在多線經治的晚期B細胞淋巴瘤患者中表現出良好的耐受性,截至目前在10個劑量組中未報吿有劑量限制性毒性(DLT)。

基石藥業首席執行官、研發總裁兼執行董事楊建新博士表示:“非常高興我們的ROR1 ADC在臨牀上持續顯示良好的抗腫瘤活性,可控安全性及耐受性,本次ASH年會公佈了CS5001在更多晚期淋巴瘤患者中的單藥臨牀數據,這些患者絕大部分已經經歷3線治療失敗。我們在霍奇金淋巴瘤與非霍奇金淋巴瘤中均能觀察到CS5001令人鼓舞的抗腫瘤活性,特別在 DL8 (125μg/kg)13例可評估的晚期B細胞淋巴瘤患者中,ORR更是達到了76.9%,我們也會在即將開啟的Ib期研究中進一步評估和優化該劑量。由於CS5001在侵襲性和惰性淋巴瘤中均已展現初步療效,我們更加堅信CS5001具有廣闊的臨牀開發前景和極大的市場競爭力。我們將加快推進CS5001的開發進程,希望早日能為淋巴瘤患者帶來全新的治療選擇。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account